Articles tagged with Blood Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers found a 55% reduction in lymphoma risk and a 40% overall reduction in blood cancer risk among bariatric surgery patients. Women with high blood sugar at the start of the study benefited most from the surgery.
Researchers at the Swiss Cancer Center Léman have discovered a way to prolong the functionality of CAR-T cells, which are used against blood cancers. By inhibiting a specific metabolic mechanism, they created CAR-T cells with enhanced immune memory, capable of fighting tumour cells for longer.
Dr. Hung Nguyen is studying how medium chain fatty acid foods like coconut oil and avocados affect GVHD severity and mortality in transplant patients. His goal is to develop a dietary approach that reduces inflammation and corticosteroid use, improving patient outcomes for blood cancers.
Researchers have discovered that NSD2 triggers aggressive myeloma by activating PKCα, leading to excessive lactate production. This study presents potential targets for improved treatment of high-risk myeloma subtypes.
The National Institute of General Medical Sciences has awarded a five-year grant to Sylvester Comprehensive Cancer Center researchers to better define the role of XPO1 in cancer. XPO1 is a nuclear export protein shown to play a role in many cancer types, including solid tumors and blood cancers.
Researchers developed a new strategy to target CD45, a surface marker found on nearly all blood cells, using CRISPR base-editing. This approach aims to overcome challenges in CAR T cell therapy, which currently targets specific cancer types, and could expand treatment options for virtually all blood cancers.
A team of KAUST researchers has found a critical protein that regulates cell division and proliferation in breast cancer and leukemia. Their work clears the way for the development of targeted drugs by refuting recent challenges to their approach.
Researchers identified how low TET2 levels fuel rapid growth of acute myeloid leukemia in animal models. The study found that TET2 deficiency sets off biochemical changes enhancing the cancer's ability to spread. This discovery highlights potential therapeutic targets for treating aggressive bone marrow cancer.
A new study found that around one in five people with compromised immune systems have no COVID-19 antibodies after three or more vaccinations. The MELODY study identified specific groups at higher risk of not producing antibodies, highlighting the need for targeted interventions and booster vaccines.
Researchers explore CDK9 inhibitors as a promising combination partner in treating hematological malignancies. They discuss the role of cyclin-dependent kinases (CDKs) in these diseases and highlight the potential synergism with other drugs.
A new study highlights the difficulty in diagnosing blood disorders like myelodysplastic syndromes/neoplasms (MDS), which can lead to treatment mistakes. The researchers found that expert pathologists disagreed with local pathologists' diagnoses in about 20% of cases, leading to wrong initial treatments for patients.
A multicenter team has identified three risk biomarkers for chronic graft-versus-host-disease, which can be measured at 90 days after transplantation. These markers include MMP3, DKK3, and CXCL9, which are associated with fibrosis, inflammation, and immune cell attraction.
A study of 800 Dutch children found that modified treatment protocols increased the five-year survival rate for all children with acute lymphatic leukemia to 94%. The modifications resulted in a three times lower risk of disease recurrence, especially in children with an aggressive form of leukemia.
A new tool has been developed to quantify public knowledge of blood cancer symptoms, revealing notable gaps in awareness. Nearly 70% of people were unaware of night sweats as a symptom, while unexplained weight loss and bleeding were most recognized. The tool also explores patient enablement and its impact on seeking medical help.
A novel association of t(5;17) with t(8;21) has been reported in an acute myeloid leukemia (AML) patient, resulting in a RUNX1-RUNX1T1 rearrangement. The patient received chemotherapy and stem cell transplantation, highlighting the importance of this rare translocation.
Researchers investigate MCL-1i-induced Mcl-1 protein accumulation and its implications in B-cell malignancies. The study reveals a complex mechanism contributing to MCL-1 protein stability upon treatment with MCL-1 inhibitors.
Patients with GATA2 deficiency have impaired ability to produce immune cells, leading to increased risk of recurrent infections and blood cancers. The study's findings suggest that a zebrafish model may help develop new treatments to slow or reverse the disease.
Researchers have created a new prediction tool to evaluate the benefits of blood cancer treatments, filling a gap in previous versions. The ESMO-MCBS:H v1.0 tool uses a validated algorithm to assess clinical benefits, survival data, and quality of life, providing a transparent assessment for clinicians.
Researchers found that leukemia cells use messenger particles to navigate and release molecular cargo at distant sites, driving cancer metastasis. A potential therapeutic strategy involves targeting these particles with an antibody drug that blocks E-selectin activity.
Scientists from Institut Pasteur and Inserm discovered that CD4 T cells can remotely neutralize tumor cells by producing interferon gamma, offering new hopes for patients with incomplete responses to CAR T cell therapy. This study raises the possibility of personalized treatment approaches using larger quantities of CD4 CAR T cells.
The Phase 3 S1826 trial demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma treated with nivolumab and chemotherapy. The therapy was well-tolerated, with few serious immune-related side effects.
Research found an association between Agent Orange exposure and increased risk of developing myeloproliferative neoplasms, a precursor to deadly leukemias. The study analyzed data from 93,269 veterans and found possible links to cardiovascular factors like blood clots and bleeding.
A team from the University of Tsukuba has discovered that the enzyme ELOVL6 plays a significant role in the development of acute myeloid leukemia, a type of blood cancer. The study found that high levels of ELOVL6 are linked to shorter survival rates for leukemia patients.
Researchers from the UCLA Jonsson Comprehensive Cancer Center are presenting findings on combination therapies for breast cancer and a potential new treatment for patients with recurrent glioma. A phase 3 study evaluating vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation is also be...
Dr. John H. Bushweller's team at UVA Cancer Center is developing novel drugs to block abnormal proteins that cause pediatric leukemia. The new approach aims to improve efficacy and reduce toxicity, potentially leading to better patient outcomes.
A new Northwestern Medicine study found young adult cancer survivors (18-39 years old) are 2.6 times more likely to develop heart failure when treated with anthracyclines. The incidence is highest among leukemia and other specific cancer types.
Researchers at Indiana University School of Medicine discovered a strong association between obesity and clonal hematopoiesis of indeterminate potential (CHIP), a blood condition that increases the risk of blood cancer. The study found that obesity causes inflammation, which can lead to rapid growth of mutated blood cells.
Research reveals both metabolically healthy and unhealthy obesity types linked to increased risk of various obesity-related cancers, with stronger association in metabolically unhealthy obesity. Metabolically unhealthy women face higher risks for endometrial, liver, and kidney cancers.
Researchers have engineered a new CRISPR-based drug candidate targeting E. coli directly while preserving the microbiome. The innovative treatment has shown promise in reducing E. coli burden in mice and is now in phase 1 clinical trials to treat blood cancer patients and prevent deadly infections.
A phase 2 clinical trial testing a treatment combining standard chemotherapy with azacitidine showed nearly 90% of patients with aggressive T-cell lymphoma achieved complete remission. The treatment, which targets gene-silencing marks on DNA, has an estimated two-year progression-free survival rate of 69.2%.
Researchers at ETH Zurich have developed a new method called pharmacoscopy to test treatment options for multiple myeloma patients. This high-throughput screening platform analyzes the reactions of cancer cells to various treatments, offering personalized therapeutic strategies.
Blinatumomab immunotherapy significantly improves the survival rate of babies with aggressive acute lymphoblastic leukemia (ALL), from 66% to 93%, while reducing side effects. The treatment is now standard for babies worldwide.
A study of 7807 children found no increased risk of brain tumours, leukemia, or lymphoma after a single CT scan. However, exposure to 4 or more scans before adulthood significantly increases the risk of intracranial tumours, leukemia, and non-Hodgkin lymphoma
A new method, CloneTracer, distinguishes between cancerous and healthy stem cells in acute myeloid leukemia (AML). The study reveals two distinct stem cell compartments and shows that progenitor cells respond better to therapy. This finding paves the way for developing new techniques to predict patient response to chemotherapy.
Researchers at Moffitt Cancer Center have identified a critical pathway in the development of MYC-driven lymphoma, involving the chemical modification of eIF5A with hypusine. Inhibiting this process prevents lymphoma development and progression in mouse models, offering new therapeutic strategies.
A UK Biobank study found that cancer survivors may be at long-term increased risk of cardiovascular disease, regardless of traditional risk factors. Those with previous breast or blood cancers were found to have the greatest risk, with significant changes in heart size and function detected on MRI scans.
Acute myeloid leukemia is a cancer that affects blood cells and can lead to infection, anemia, and easy bleeding. The Georgia Cancer Center has received a $2.3 million grant to study how cancer cells resist treatment and propose new options to improve patient survival.
Researchers at The Mount Sinai Hospital have created versatile disease models of acute myeloid leukemia (AML), allowing for accurate study of the cancer's progression and response to drugs. These models, derived from induced pluripotent stem cells, can mimic different stages of AML and are nearly identical to those found in patients.
Researchers at Vanderbilt University Medical Center have discovered a new way to measure the growth rate of precancerous clones of blood stem cells using a technique called PACER. The findings suggest that drugs targeting the gene TCL1A may be able to suppress clonal growth and associated cancers.
Researchers at St. Jude Children's Research Hospital developed a novel combination therapy approach that uses both BET and GSK3 inhibitors against KMT2A mutated leukemia, overcoming drug resistance without increasing toxicity. The approach was confirmed in cell lines and xenograft mouse models, and holds promise for further development.
A study by Linköping University researchers found that blood stem cells from leukemia patients remain in the bone marrow, but become defective over time, leading to long-term effects on blood formation. This discovery may explain why many leukemia survivors experience blood cell function disorders later in life.
Researchers discuss cortactin's impact on cancer progression by modulating the Wnt5a/ROR1 signaling pathway. Cortactin expression is found in various cancers, including breast and chronic lymphocytic leukemia, suggesting its potential role in promoting metastasis.
A landmark study links iron regulation to a rare blood cancer, revealing that restricting iron access to the bone marrow can reduce red blood cell production in patients with polycythemia vera. Clinical trials are underway for a potential new treatment using a drug that controls iron regulation.
A new study reveals that patients with blood cancers experience significant improvement in their reported well-being after receiving CAR T-cell therapy. The therapy not only improves physical symptoms but also anxiety and depression symptoms.
A new study of over 200 people with premature aging syndromes caused by abnormally short telomeres suggests that chromosomal instability may not be the reason for increased cancer risk. Instead, immune system cells that age and die prematurely may play a role in cancer predisposition.
Researchers at the University of Missouri have developed a process for marking transplanted donor bone marrow cells, allowing them to target only cancerous cells. This breakthrough offers new hope for bone marrow transplant patients with blood cancers such as lymphoma and leukemia.
Researchers found that COVID-19 vaccination generates robust T cell responses in haematology patients, on par with healthy individuals. The study provides key insights for future immunisation strategies and shows that mRNA vaccines can elicit strong T cell immunity in patients with co-morbidities.
Researchers at the University of Wisconsin-Madison have identified a specific cell population, called CD4/CD8 double positive T cells, that causes graft-versus-host disease in bone marrow transplants. The team's findings may lead to targeted treatments and improved patient outcomes.
Scientists from USC Stem Cell laboratory discovered a mechanism linking leukemic mutations to varying disease potentials, identifying RNA splicing regulator Rbm25 as a critical factor. The study found that over-contributing clones of blood stem cells produce excessive myeloid cells, leading to potential leukemia development.
Researchers at Lund University discovered a novel mechanism linking RNA splicing to the development of leukemia in myelodysplastic syndrome patients. The study highlights the critical role of core spliceosome component SF3B1 and its regulation by N6-methyladenosine (m6A) modification, which provides a
Researchers at Mayo Clinic have made significant progress in treating multiple myeloma using chimeric antigen receptor therapy (CAR-T cell therapy), which has shown a median progression-free survival of 13.3 months compared to 4.4 months for standard treatment regimens.
Researchers have identified two potential molecular targets, CSF1R and CD86, that can be used to develop CAR-T cells effective against acute myeloid leukemia. The study's findings demonstrate the potential of AI-assisted analysis in discovering new treatment options.
Children with Down syndrome are highly vulnerable to developing aggressive leukaemia due to a defect in the RUNX1 gene, which regulates blood cell formation. Researchers have identified a specific variant of the gene that promotes leukaemia development and discovered potential therapeutic approaches to correct this malfunction.
A team of researchers has discovered a potential therapeutic that can synergize with existing drugs to more effectively kill certain leukemia cells. The therapy targets a DNA repair protein and shows promise in clinical trials.
Researchers found that FABP5 is linked to more aggressive disease and poorer survival in multiple myeloma. Patients with higher FABP5 expression had significantly shorter time to disease progression and overall survival.
Researchers developed a blood test to detect residual leukemia in AML patients before bone marrow transplant, showing that those with persistent mutations had higher risks of relapse and lower survival rates. The study supports ongoing research on precision medicine and personalized post-transplant care.
Researchers have discovered that the enzyme COASY plays a critical role in regulating red blood cell production in the bone marrow. Vitamin B5 supplementation and another metabolite increased the maturation of red blood cells in patients with Myelodysplastic syndromes, offering new hope for alternative treatments.
Researchers found that severe herpesvirus infections can strongly activate host cellular immunity, leading to a therapeutic effect on refractory adult T-cell leukemia/lymphoma. This activation may play an important role in the survival of patients with this intractable disease.
A study published in CANCER found that children with acute lymphoblastic leukemia living along the US-Mexico border had a lower five-year survival rate compared to those in non-border areas. The research highlights existing disparities in pediatric cancer outcomes, particularly among Hispanic and Black communities.
Researchers at VCU Massey Cancer Center have discovered a novel combination therapy that dramatically suppresses the growth of AML cells, including those resistant to venetoclax. The dual mTORC1/2 inhibitors synergistically enhance AML cell death when paired with venetoclax.